SeroCT RT C. trachomatis IgG ELISA Assay


The Eagle Biosciences SeroCT RT IgG ELISA Assay kit is intended for the detection of IgG antibodies specific to C.trachomatis in human serum. The SeroCT RT IgG ELISA Assay kit is a new generation qualitative ELISA test which is based on Chlamydia trachomatis specific synthetic peptides. SeroCT RT is used as an aid in the diagnosis of C.trachomatis specific infection. SeroCT RT IgG is intended to be run and interpreted in conjunction with the Savyon SeroCT RT IgA kit. The Eagle Biosciences SeroCT RT IgG ELISA Assay Kit is for Research Use Only and is not intended for diagnostic or therapeutic purposes.

SKU: 1181-01 Categories: , ,

SeroCT RT C. trachomatis IgG ELISA Assay

The SeroCT RT C. trachomatis IgG ELISA Assay is For Research Use Only

Size: 1×96 wells
Sensitivity: Cut-Off Control
Incubation Time: 1.5 hours
Sample Type: Serum
Sample Size: 25 µL

Assay Principle

SeroCT RT Plates are coated with C. trachomatis specific peptides. Serum to be tested is diluted and incubated with the pre-coated SeroCT RT plate 30 minutes at Room Temperature (RT). In this step C. trachomatis specific antibodies are bound to the immobilized C. trachomatis peptides. Non-specific antibodies are removed by washing. Anti-human IgG conjugated to horseradish peroxidase (HRP) is added and incubated 30 minutes at Room Temperature. In this step the HRP-conjugate is bound to the prebound antigen-antibody complex. Unbound conjugate is removed by washing. Upon the addition of TMB substrate, the substrate is hydrolyzed by the peroxidase, yielding a blue solution of the reduced substrate. Upon the addition of the stop solution, the blue color turns yellow and should be read by an ELISA reader at a wavelength of 450/620 nm. The absorbance is proportional to the amount of the specific antibodies which are bound to the immobilized peptides.

Related Products

SeroELISA Chlamydia IgG Assay
SeroCT C. trachomatis IgG ELISA Assay Kit
SeroCT RT C. trachomatis IgA ELISA Assay Kit

Additional Information

Assay Background

Chlamydia is a gram-negative obligate intracellular bacteria that causes acute and chronic diseases in mammalian and avian species. The genus Chlamydia is comprised of four species: C.trachomatis, C.pneumoniae, C.psittaci and C. pecorum. C.trachomatis is divided into 15 serovars (5-8). Serovars A, B, Ba and C are agents of trachoma, the leading cause of preventable blindness endemic in third world countries. Serovars L1-L3 are the agents of lymphogranuloma venereum. Serovars D-K are the common cause of sexually transmitted genital infection worldwide: cervicitis, endometritis/ salpingitis (10) in females and urethritis (11) in both males and females. Endometritis/salpingitis can lead to tubal occlusion with a higher risk of extrauterine pregnancy and infertility. Genital infection may cause an acute and persistent infection occasionally without any clinical symptoms. Generally, these infections are treatable once they are diagnosed. However without any treatment the infection may progress to a severe chronic inflammation leading to infertility, ectopic pregnancy, induced abortion or child delivery. Moreover, infants to infected mothers may be infected during birth, leading to conjunctivitis or pneumonia. The serology of C. trachomatis is more interesting in cases of chronic infections than in acute infections. C.pneumoniae is an important respiratory pathogen in humans and causes up to 10% of community-acquired pneumonia cases. It has been associated with acute respiratory diseases, pneumonia, asthma, bronchitis, pharyngitis, acute chest syndrome of sickle cell disease, coronary heart disease, and Guillain-Barre syndrome. C.psittaci infects a diverse range of host species from molluscs to birds to mammals and also causes severe pneumonia. In animals, C.psittaci and C.pecorum are capable of inducing diverse disease syndromes like pneumonia, enteritis, polyserositis, encephalitis and conjunctivitis. Serological testing, now an established approach in many countries, has been shown to provide a comprehensive answer for the detection of C. trachomatis infection. In suspected deep-seated infection, serum sampling reduces the necessity for invasive procedures, which are required for direct antigen detection. In cases of lower urogenital infections, collection limitations such as effectiveness of scrape sampling procedure, specimen handling and transportation difficulties have to be weighed. Above all, the issue remains that most Chlamydia infections are asymptomatic. Therefore an infection may persist for a long time, ascend the upper genital tract, causing deep and chronic infections, and increase the probability of false negative results in direct antigen detection. Serological testing for Chlamydia trachomatis, through the detection of various specific antibodies, is today an effective and highly accepted option. New and accurate technologies apply the immuno markers IgM, IgA and IgG to characterize the presence and stage of infection. Specific IgM is indicative of acute Chlamydia infections. Absence does not; however preclude the presence of on-going infection, especially in recurrent and chronic cases. The use of specific IgA as a marker for active Chlamydia infection has been shown to have an important role because of its short half-life time, while persisting as long as antigenic stimulation exists. IgA, however, is more suitable for post therapy follow-up. IgG is a marker for Chlamydia positive immune response in either current, chronic or past infections. Serological cross-reactions occur between the three different species of Chlamydia. Most of the serological diagnostic assays for Chlamydia use either purified elementary bodies microimmunofluorescence (MIF) and ELISA tests, lipopolysaccharides (LPS) or purified major outer membrane protein (MOMP), as antigens. Genus specific epitopes are present in all the above antigens, therefore low species specificity is observed. Moreover, a large proportion of the population has been exposed to C.pneumoniae (with no clinical signs), the prevalence of anti- Chlamydia antibodies is very high. Therefore, the differentiation between C.pneumoniae and C. trachomatis specific antibodies using conventional serological screening tests (MIF, ELISA, EIA etc.) is insufficient.

Savyon Diagnostics Ltd has developed an assay in which C.trachomatis species specific epitopes, derived from different serotypes, are used in an Enzyme-Linked Immunosorbent Assay (ELISA). The test excludes cross-species reactive epitopes and enables more accurate and more specific determination of C.trachomatis IgG and IgA antibodies.


  1. Sarov, I.B., Shemer, A.Y., Manor, E., Zvilich, M., Lunenfeld, E., Piura, B., Chaim, W and Hagay, Z.(1989). Current topics in Chlamydia trachomatis Research. In: Serio, M.(Ed). Perspectives in Andrology; Raven Press, New York,  53: 355-366.
  2. Grayston, J.T., Kuo, C.C., Wang, S.P. and Altman J. (1986). The new Chlamydia psitacci strain, TWAR, Isolated in acute respiratory tract infections. New Eng. J. Med. 315: 161-168.
  3. Grayston, J. T., Kuo, C.C., Campbell, L.A. and Wang, S.P.  (1989). Chlamydia pneumoniae sp. nov. for Chlamydia sp. strain TWAR. Int. J. Syst. Bacteriol. 39:88-90.
  4. Fukushi, H., and Hirai, K. (1992). Proposal of Chlamydia pecorum sp. nov. for Chlamydia strains derived from ruminants. Int. J. Syst. Bacteriol. 42:306-308.
  5. Stephens, R. S., Tam, M. R., Kuo, C. C. and Nowinski, R.C. (1982). Monoclonal antibodies to Chlamydia trachomatis: antibody specificities and antigen characterization. J. Immunol. 128:1083-1089.
  6. Stephens, R. S., Sanchez-Pescador, R., Wagar, E. A., Inouye, C. and Urdea, M.S. (1987). Diversity of Chlamydia  trachomatis major outer membrane protein genes. J. Bacteriol. 169:3879-3885.
  7. Yuan, Y., Zhang, Y. X., Watkins, N. G. and Caldwell, H.D. (1989). Nucleotide and Deduced Amino Acid Sequences for the Four Variable Domains of the Major Outer Membrane Proteins of the 15 Chlamydia trachomatis Serovars. Infection and Immunity. 57:1040-1049. Copyright 1989, American Society for Microbiology.
  8. Wang S.P., Kuo, C. C., Barnes, R.C., Stephens, R.S. and Grayston, J.T. (1985). Immunotyping of Chlamydia trachomatis  with monoclonal antibodies. J. Infect Dis. 152:791-800.
  9. Treharne J. D. (1985). The community epidemiology of trachoma. Rev Infect Dis. 7:760-763.
  10. Piura, B., Sarov, I., Sarov, B., Kleinman, D., Chaim, W. and Insler, V. (1985). Serum IgG and IgA antibodies specific for Chlamydia trachomatis in salpingitis patients as determined by the immunoperoxidase assay. Eur. J. Epidemiol 1: 110-116.
  11. Wang, S.P., Grayston, J.T., Kuo, C.C., Alexander, E.R., and Holmes, K.K. (1977). SeroDiagnosis of Chlamydia trachomatis infection with the microimmunofluorescence test. In: Nongonoccolcal urethritis and related infection, D. Hobson and K.K. Holmes (Eds), P. American Society for Microbiology, Washington DC. p. 237-248.
  12. Richard, L. S., Schachter, J. and Landers, D.V. z(1983).  Chlamydial Infections in Obstetrics and Gynecology. Clinical Obstetrics and Gynecology 26:143
  13. Thompson III S. E., and Dretler R. H. (1982). Epidemiology and Treatment of Chlamydial Infections in Pregnant Women and Infants. Review of Infectious Diseases 4:S747
  14. Mardh A., Ripa, T., Svensson, L. and Westrom, S.(1977). Chlamydia Trachomatis Infection in Patients with Acute Salpingitis. Chlamydia Trachomatis and Acute Salpingitis. N. Engl. J. Med. No.24 296:1377-1379
  15. Grayston J. T., Campbell, L.A., Kuo, C.C., Mordhorst, C.H., Saikku, P., Thom, D.H. and Wang, S.P. (1990). A new respiratory tract pathogen. Chlamydia pneumoniae strain TWAR. J. Infect. Dis. 161:618-625.
  16. Hahn D. L., Dodge, R. W. and Golubjatnikow, R. (1991). Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma.  JAMA 266: 225-230
  17. Saikku P., Mattila, K., Nieminen, M.S., Huttunen, J.K., Leinonen, M., Ekman, M.R., Makela, P.H., and Valtonen, V. (1988). Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infection. Lancet II:983-986.
  18. Tsunekawa, T. and Kumamoto, Y. (1989) A study of IgA and IgG titers of C. trachomatis in serum and prostatic secretion in chronic prostatitis. J.J.A. Inf. Dis. 63(2): 130-137.
  19. Kaneti, J., et al., (1988). IgG and IgA antibodies specific for Chlamydia trachomatis in acute epididymitis. Europ. Urol. 14: 323-327.
  20. Sarov, I., Kleinman, D., Cevenini, R., Holcberg, G., Potashnik, G., Sarov, B. and Insler, V. (1986). Specific IgG and IgA antibodies to Chlamydia trachomatis in infertile women. Int. J. Fertil. 31 (3):193-197.

Package Inserts

  • Instructions for Use
  • Please note: All documents above are for reference use only and should not be used in place of the documents included with this physical product. If digital copies are needed, please contact us.

Product Citations